Business Description
First Tracks Biotherapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US3371851029
Description
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 24.03 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.51 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 94.86 | |||||
9-Day RSI | 88.97 | |||||
14-Day RSI | 82.74 | |||||
3-1 Month Momentum % | -30.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.78 | |||||
Quick Ratio | 10.78 | |||||
Cash Ratio | 10.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -40.85 | |||||
ROA % | -36.95 | |||||
ROIC % | -319.89 | |||||
ROC (Joel Greenblatt) % | -1049.74 | |||||
ROCE % | -43.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.22 | |||||
Price-to-Tangible-Book | 3.22 | |||||
EV-to-EBIT | -5.4 | |||||
EV-to-Forward-EBIT | -7.18 | |||||
EV-to-EBITDA | -5.47 | |||||
EV-to-FCF | -7.75 | |||||
| Price-to-Net-Current-Asset-Value | 3.71 | |||||
| Price-to-Net-Cash | 3.76 | |||||
Earnings Yield (Greenblatt) % | -18.52 | |||||
FCF Yield % | -9.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TRAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
First Tracks Biotherapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.711 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 82.74 | ||
| 14-Day ATR ($) | 2.919379 | ||
| 20-Day SMA ($) | 19.736 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 14.72 - 38.4889 | ||
| Shares Outstanding (Mil) | 34.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
First Tracks Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
First Tracks Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
First Tracks Biotherapeutics Inc Frequently Asked Questions
What is First Tracks Biotherapeutics Inc(TRAX)'s stock price today?
The current price of TRAX is $36.24. The 52 week high of TRAX is $38.49 and 52 week low is $14.72.
When is next earnings date of First Tracks Biotherapeutics Inc(TRAX)?
The next earnings date of First Tracks Biotherapeutics Inc(TRAX) is .
Does First Tracks Biotherapeutics Inc(TRAX) pay dividends? If so, how much?
First Tracks Biotherapeutics Inc(TRAX) does not pay dividend.
Guru Commentaries on NAS:TRAX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on First Tracks Biotherapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers